SVB Wealth LLC Makes New $478,000 Investment in Kenvue Inc. (NYSE:KVUE)

SVB Wealth LLC purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 22,392 shares of the company’s stock, valued at approximately $478,000.

Several other institutional investors and hedge funds have also made changes to their positions in KVUE. Alerus Financial NA boosted its holdings in Kenvue by 0.3% in the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after purchasing an additional 491 shares during the period. Kiley Juergens Wealth Management LLC grew its position in shares of Kenvue by 1.9% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after buying an additional 500 shares during the last quarter. Principle Wealth Partners LLC raised its stake in Kenvue by 3.7% during the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after acquiring an additional 500 shares during the period. White Pine Capital LLC lifted its holdings in Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock worth $1,165,000 after acquiring an additional 542 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its holdings in Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock worth $54,000 after acquiring an additional 568 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Down 1.5 %

Shares of NYSE:KVUE opened at $23.44 on Wednesday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market cap of $44.79 billion, a P/E ratio of 44.22, a P/E/G ratio of 2.62 and a beta of 1.45. The company has a 50 day moving average of $21.54 and a 200-day moving average of $22.30.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.50%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s payout ratio is currently 154.72%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on KVUE shares. UBS Group dropped their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Canaccord Genuity Group lowered their price objective on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Piper Sandler boosted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Barclays lowered their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $23.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.